

Pediatric Oncology Report 2023


DATA FROM 2019 - 2023






Sidra Medicine


Pediatric Oncology Report 2023





Contents

| | |
|---|----|
| Welcome | 3 |
| Meet the Team | 4 |
| Interviews – Dr. Ozer and Dr. Al Kharazi | 6 |
| Sidra Medicine Pediatric Cancer Registry | |
| Overview | 08 |
| Central Nervous System Tumors | 10 |
| Leukemia | 12 |
| Interviews – Clinical & Research Teams | 14 |
| Biobank | 16 |
| Snapshots of Patient Reports | |
| Personal Cancer Genome Reporter | 18 |
| Fusion Reports | 20 |
| Cancer Predisposition Sequencing Reporter | 22 |
| Methylation Profiling Report | 24 |
| Publication Highlight | 26 |
| A Journey of Hope | 27 |
| Cancer Grant Awards | 28 |
| Publication List | 29 |
| Acknowledgement | 34 |





From left to right:

Dr. Erdener Ozer, Division Chief Anatomical Pathology Division | **Dr. Wouter Hendrickx**, Lead Principal Investigator, Pediatric Precision Oncology Initiative | **Dr. Ayman Saleh**, Division Chief Oncology and Hematology Division | **Dr. Ian Pople**, Division Chief Neurosurgery Division

Welcome Message

We are pleased to present Sidra Medicine's "Pediatric Cancer and Precision Oncology in Qatar" 2023 Annual Report.

The report is a joint update from the Pediatric Precision Oncology Initiative, the Oncology and Hematology Division, the Anatomical Pathology Division, and the Neurosurgery Division at Sidra Medicine.

Since opening our main hospital in 2018, Sidra Medicine has become the country's sole healthcare provider for the care and treatment of children and young people with cancer. To support our personalized medicine strategy, we initiated the Sidra Medicine Pediatric Precision Oncology Initiative in 2019, which works closely with our pediatric cancer services. This initiative has been funded by Sidra Medicine Research Branch IRF and QRFI PPM5.

This close synergy between our clinical and research divisions grants us a comprehensive understanding of our patients' characteristics and epidemiology but more importantly to develop personalized precision medicine treatment protocols.

The collaboration has also led to the creation of two significant assets: the Qatar Pediatric Cancer Registry and The Sidra Pediatric Cancer Biorepository (SPCB). The former collects comprehensive clinical data, while the latter seeks consent from patients to donate materials no longer needed for diagnosis, thus enabling pertinent research for our local population. These repositories, built on the expertise we have acquired over the years, are now our springboard to precision oncology.

Presenting data from 2019 to 2023, we aim to share the rich data repository that guides our clinicians in identifying rare targetable somatic mutations and facilitating patient enrollment in worldwide clinical trials. These data allow us to spotlight novel molecular targets in specific patient subgroups, paving the way for new biomarkers and therapeutic strategies.

Worldwide, the incidence rates of childhood cancer range between 50 and 200 per million children. In Qatar, we find ourselves in the center of this spectrum with a rate of 126 per million children. Our patient population at Sidra Medicine primarily consists of individuals of Arab and Asian descent, making up 60.26 percent and 31.79 percent of our patients, respectively. The most prevalent diagnoses are Leukemia (31%) and Central Nervous System malignancies (23%), followed by Germ cell tumors, renal tumors, Neuroblastoma, and Sarcomas.


As we improve the timing and rate of consent acquisition, we edge closer to providing molecular profiling at the point of diagnosis. This wealth of data, which surpasses current clinical requirements, is the result of our strategy to align people and technologies, ensuring harmony between pathology, research, and clinical care; an equally challenging and rewarding endeavor.


We firmly believe that these initiatives will empower pediatric patients to benefit from the seismic shift in cancer treatment, a revolution led by targeted and immunotherapy trials. This deeper understanding of tumors, exploring genetic determinants, epigenetic classification, immune phenotypes, mutational load, or intratumoral heterogeneity, gives us insights into adapting groundbreaking therapies for our pediatric patients.

Our work is at the forefront of personalizing precision medicine for every pediatric cancer patient in Qatar. It is our hope that this shared knowledge will enhance understanding and contribute to improved cancer care outcomes.

Dr. Wouter Hendrickx,
Lead Principal Investigator,
Pediatric Precision Oncology Initiative

Meet the Team





INTERVIEWS

Pioneers in Pediatric Pathology and Neurosurgery

Dr. Erdener Ozer is the Division Chief of Anatomical Pathology and joined our hospital in 2021. He is also a senior attending physician who manages the integrated digital pathology reporting for a full range of pediatric surgical pathology and placental work, as well as autopsies. In addition to his clinical role, he conducts research as a leading PI and co-PI. His special research interest is in the genomic pathology of pediatric tumors, including neuroblastoma and pediatric brain tumors. He is also part of the biobanking facility for the Sidra Pediatric Precision Oncology Initiative.

“I am particularly interested in pediatric cancer research focused on genetic and molecular profiling, biomarker discovery, tumor microenvironment, novel treatments like immunotherapy, and precision medicine. These areas offer insights into the underlying mechanisms of cancer, enable early and accurate diagnosis, inform the development of targeted therapies, and help tailor treatments to individual patients. This approach improves treatment outcomes and reduces adverse effects, ultimately enhancing the quality of life for pediatric cancer patients.”

Some of the diagnostic challenges we have encountered in pediatric pathology have been due to the rarity and diversity of pediatric cancers, non-specific early symptoms, difficulty in obtaining adequate biopsy samples, rapid disease progression, genetic and molecular heterogeneity, and the lack of standardized treatment protocols for some tumors.

Additionally, we must stay current with evolving diagnostic criteria, coordinate effectively with various specialists, and often deal with figuring out the clinical indications to perform advanced diagnostic tools. Continuous education, interdisciplinary collaboration, and the knowledge of how to use advanced technologies are essential to overcoming these challenges and ensuring accurate and timely diagnoses.”




Dr. Erdener Ozer and Dr. Khalid Al Kharazi

Dr. Khalid Al Kharazi is a senior attending/consultant neurosurgeon and director of the pediatric neurosurgery fellowship program. His division manages neurosurgical conditions for most children in Qatar, from the first day of life to the age of 18 years. They provide comprehensive care starting from the diagnosis of the condition, preoperative planning, and surgical approaches, utilizing the best neurosurgical instruments and equipment, in addition to the team’s extensive experience.

“Our neurosurgery capabilities play an important role in pediatric cancer treatment. Our team provides top-notch care starting from diagnosis through to surgical intervention. We utilize advanced imaging technologies such as the latest CT and MRI machines, and our expert neuroradiologists play a crucial role in diagnosing conditions accurately.

The cancer tissue is meticulously analyzed by our experienced neuropathologists, and if needed, we seek further support from Sidra Medicine partners overseas for molecular genetics and other advanced diagnostic tools. Our collaboration with research teams ensures that we offer cutting-edge treatment options, improving patient outcomes significantly.


Seeing children with malignant tumors surviving and returning to the clinic for follow-up with happy parents is incredibly motivating. Medicine is a science that never stops progressing, and I stay current with the latest research and developments by attending and organizing scientific meetings, collaborating with experts in the field, and exploring new research studies. The opportunity to make a significant difference in children's lives and contribute to advancements in pediatric oncology keeps me dedicated to this field.”




SIDRA MEDICINE PEDIATRIC CANCER REGISTRY

Overview


Types of Pediatric Solid Cancer Presented at Sidra Medicine (69%)




Types of Pediatric Non-solid Cancer Presented at Sidra Medicine (31%)




Ethnicity of Our Patients




Arab Population




Asian Population




Patients with Metastasis at Diagnosis




Treated Abroad by Year




Evolution of the Modalities of Treatments Applied at Sidra Medicine



Status of Patients by Their Year of Diagnosis




Traditional Kaplan Meir Survival Plot of Our Patient's Population by Cancer Type




SIDRA MEDICINE PEDIATRIC CANCER REGISTRY

Central Nervous System Tumors


Distribution of ICDO3 Codes of Our CNS Patients




Cancer Grade of CNS Tumors at Diagnosis by Year




Response of Our CNS Patients After Finishing Primary Treatment



ICDO3 Codes by Year of Diagnosis



Treatment Protocols Applied to Our Patient Population by Year of Diagnosis




SIDRA MEDICINE PEDIATRIC CANCER REGISTRY

Leukemia


Distribution of ICDO3 Codes of Our Leukemia Patients




Response of Our Leukemia Patients After Finishing Primary Treatment by Year of Diagnosis



ICDO3 Codes by Year of Diagnosis



Treatment Protocols Applied to Our Patient Population by Year of Diagnosis





TEAM INTERVIEWS

Balancing Compassion, Care, and Cutting-Edge Research

Mohammed Anas is a Clinical Nurse Leader at the Hematology Oncology division. Specializing in pediatric oncology nursing allows him to use his skills in children's health in the fight against cancer. Anas balances the emotional challenges of his work by maintaining a professional yet compassionate demeanor, building strong relationships with patients and their families, and providing emotional support alongside exceptional care.

“My journey into pediatric oncology nursing was driven by my deep passion for caring for children and a personal experience with a young family member’s illness. The unique challenges and rewards of pediatric care, combined with the resilience of children battling cancer, solidified my decision to specialize in this field.

Balancing the emotional demands of working with young cancer patients involves maintaining a compassionate yet professional approach. Building strong relationships with patients and their families helps me provide emotional support and deliver exceptional care. One memorable experience was supporting a young patient through treatment side effects with play therapy and communication, ultimately seeing her regain her playful spirit and successfully complete treatment.

I’m motivated by the courage of my young patients and the progress in treatment advancements. I stay dedicated by keeping up with the latest research through conferences, workshops, and online resources. As a clinical nurse involved in research, I bridge the gap between patient care and research, offering valuable insights, educating patients, and contributing to advancements that improve outcomes in pediatric oncology.”

Arianne Alejo is a Clinical Nurse at the Hematology Oncology division. She has experience in both adult and childcare. Arianne finds it an honor to be part of the patient and family journey throughout their treatment process, despite the stressful situations. Her dedication to continuous learning includes participating in clinical trials, and professional development courses, and attending conferences and workshops to stay current with the latest research and developments in pediatric oncology.

“I began specializing in pediatric hematology oncology nursing in 2013 after transitioning from adult medical/surgical care. Initially, the shift was daunting, but the support from my colleagues made a significant difference. Despite the stress of the role, it’s a privilege to be involved in the treatment journeys of children and their families.

To handle the emotional challenges of this career, I focus on maintaining a positive outlook and setting boundaries to prevent burnout. The most memorable aspect of my work is seeing patients overcome cancer and return to a normal life, which provides immense personal and professional satisfaction.

My dedication to this field is fueled by a deep passion for oncology nursing and a desire for professional growth. I stay current with the latest research by engaging in continuous learning and participating in clinical trials. Although I initially wasn't aware of the research role, my involvement has allowed me to contribute innovative ideas that enhance patient care and outcomes."

Aisha Khalifa is a research coordinator working in the Clinical Trials Office (CTO). She has been a part of various studies from different specialties. Aisha's work is crucial in running smooth and ethical studies, which are vital for obtaining diverse and representative samples. Her efforts contribute significantly to the pediatric oncology research at our hospital.

"At Sidra Medicine, research coordination involves managing studies across various departments like oncology, genetics, and NICU. The role includes overseeing patient recruitment, ensuring protocol compliance, and maintaining accurate documentation. The advanced facilities and multidisciplinary team at Sidra Medicine support innovation in pediatric oncology research, enabling impactful studies with cutting-edge technology.

I'm motivated by the opportunity to make a significant impact on children and their families. To stay current with advancements in the field, I attend conferences, participate in professional development, and collaborate with colleagues. These efforts help me stay updated on the latest trends and innovations in pediatric oncology.

Enrolling pediatric oncology patients in research presents several challenges. I face issues such as obtaining informed consent, managing the emotional and physical burdens on patients and families, and addressing logistical challenges like coordinating study visits with treatment schedules. Balancing ethical concerns with research needs is also crucial."

Tumour Biology and Immunology Laboratory: Apryl Sanchez has been a Research Specialist I at Sidra Medicine since 2019. She manages the Sidra Pediatric Cancer Biobank samples and has helped establish standard operating procedures (SOPs) for sample management. Apryl also handles sample requests, transfers samples under controlled conditions, and conducts continuous quality monitoring. She is particularly fascinated by the genetic and molecular underpinnings of pediatric cancers, which directly influence the development of targeted therapies and improve patient outcomes.


"I've been involved in managing the Sidra Pediatric Cancer Biobank samples and establishing standard operating procedures for sample management. My responsibilities include coordinating the collection of biospecimens, logging them into the PRIME (Precision Research Information Management Environment) system, and performing processing tasks such as DNA and RNA extraction. I also ensure accurate sample labeling, storage, and data entry, maintain proper cryopreservation, and handle sample requests while conducting continuous quality monitoring.

I'm particularly fascinated by the genetic and molecular aspects of pediatric cancers. This research area not only enhances our scientific understanding but also directly impacts the development of targeted therapies and molecular diagnostics. The Expedited Genomic Oncology Profiling (eGOP) workflow stands out to me as it provides detailed genetic information swiftly, enabling personalized treatment plans for our young patients and significantly improving their outcomes.


Automation in sample processing has made a significant impact on my work, streamlining our workflow and increasing accuracy in DNA and RNA extractions. Advances in next-generation sequencing and bioinformatics have enhanced our ability to screen for mutations, offering detailed insights into each patient's unique cancer profile. While managing biospecimens presents challenges, such as ensuring accuracy and integrity, it also offers opportunities to innovate and collaborate across departments, making our work both rewarding and impactful."

SIDRA MEDICINE PEDIATRIC CANCER Biobank

Types of Pediatric Solid and Non-solid Cancer
in the Biobank




Biobank Ethnicity



Consent and Sampling Rates Per Cancer Type by Year of Diagnosis


Consent Rate for CNS and Miscellaneous Intracranial and Intraspinal Neoplasms




Consent Rate for Neuroblastoma and other peripheral Nervous Cell Tumors




Consent Rate for Renal Tumors




Consent Rate for Soft Tissue and Other Extraosseous Sarcomas




Consent Rate for for Germ Cell Tumors, trophoblastic Tumors, and Neoplasms of Gonads




Other Consent Rate for Solid Tumors



Consent Rate for Lymphoid Leukemias



Consent Rate for Acute Myeloid Leukemias



SNAPSHOTS OF PATIENTS' REPORTS

Personal Cancer Genome Reporter (PCGR)


Somatic mutations are changes to a person's DNA that occurs after conception to any cell that isn't a germ cell (egg or sperm cell). Somatic or acquired genomic variants are the most common cause of cancer. In the SPCB, we are generating a PCGR report for each patient that interprets both somatic SNVs/InDels and copy number aberrations. The prioritization of SNV and InDels found in the tumor sample is done according to a four-tiered structure, adopting the joint consensus recommendation by Association for Molecular Pathology and American College of Medical Genetics and Genomics.

- Tier 1: Variants of strong clinical significance - constitutes variants linked to predictive, prognostic, or diagnostic biomarkers.
- Tier 2: Variants of potential clinical significance - constitutes other variants linked to predictive, prognostic, or diagnostic biomarkers.
- Tier 3: Variants of uncertain clinical significance - includes other coding variants found in oncogenes or tumor suppressor genes.
- Tier 4: includes other coding variants.

Global Variant Datatable

| SYMBOL | CONSEQUENCE | PROTEIN_CHANGE | VARIANT_CLASS | TIER | GENOMIC_CHANGE |
|--------|--------------------|---------------------|---------------|--------|------------------|
| FGFR1 | missense_variant | p.Lys687Asn | SNV | TIER 3 | 8:g.38272306C>G |
| FGFR1 | missense_variant | p.Asn577Lys | SNV | TIER 3 | 8:g.38274849G>T |
| MYO3B | missense_variant | p.His361Asn | SNV | TIER 4 | 2:g.171239595C>A |
| SCN5A | frameshift_variant | p.Arg1362SerfsTer12 | deletion | TIER 4 | 3:g.38601796AC>A |
| XCR1 | missense_variant | p.Glu260Lys | SNV | TIER 4 | 3:g.46062662C>T |


Allelic Support Plot




Molecularly Targeted Trials

| | NCT_ID | TITLE | OVERALL_STATUS | CONDITION | KEYWORD | INTERVENTION | PHASE |
|---|-------------|--|--------------------|-----------------------------------|--|---|-------|
| 1 | NCT02887040 | Study of Antineoplaston Therapy + Radiation vs. Radiation Only in Diffuse, Intrinsic, Brainstem Glioma | Not yet recruiting | Brainstem glioma | Radiotherapy | Antineoplaston A10 , Antineoplaston AS2-1 | 3 |
| 2 | NCT04425798 | Connectivity Alterations After Levetiracetam Application | Not yet recruiting | Glioma | Radiotherapy | | |
| 3 | NCT02432417 | The Addition of Chloroquine to Chemoradiation for Glioblastoma, | Not yet recruiting | Glioblastoma | Chemoradiotherapy, Immunotherapy, Radiotherapy | Chloroquine | 2 |
| 4 | NCT04141319 | Effects of Pre-emptive Scalp Infiltration With Ketorolac and Ropivacaine for Post-craniotomy Pain | Not yet recruiting | Neoplasm of brain | Radiotherapy | Ropivacaine , Ketorolac , Epinephrine | 4 |
| 5 | NCT04319276 | Oral Gallium Maltolate for the Treatment of Relapsed and Refractory Glioblastoma | Not yet recruiting | Glioblastoma | Radiotherapy | Gallium Maltolate | 1 |

MSI Evidence I: Mutational Burden of Indels



MSI Evidence II






SNAPSHOTS OF PATIENTS' REPORTS

Fusion Reports

A fusion gene is defined as two genes that are joined so that they are transcribed and translated as a single unit. Fusion proteins produced by this change may lead to the development of some types of cancer.

We are generating a fusion report for each patient through implementing a bioinformatics analysis pipeline for RNA sequencing using 3 tools for detecting and visualizing fusion genes.

Dashboard Fusion Summary




List of Detected Fusions

| Fusion Gene | Found in DB | arriba | fusioncatcher | starfusion | Tools hits | Score |
|--------------------|-------------|--------|---------------|------------|------------|-------|
| PAX7--FOXO1 | FusionGDB | ✓ | ✗ | ✓ | 2 | 0.243 |
| SETBP1--AL357509.1 | Not found | ✓ | ✗ | ✓ | 2 | 0.143 |
| KANSL1--ARL17B | Not found | ✗ | ✗ | ✓ | 1 | 0.071 |
| AC092691.1--LSAMP | Not found | ✗ | ✗ | ✓ | 1 | 0.071 |

Related Diseases

| Gene (Disease ID) | Disease Description | Disease Probaility (%) | Disease Publications | Disease Source |
|-------------------|-----------------------------|------------------------|----------------------|--------------------------|
| FOXO1 (C0206655) | Alveolar Rhabdomyosarcoma | 64.61 | 0 | CTD_human, HPO, ORPHANET |
| PAX7 (C0206655) | Alveolar Rhabdomyosarcoma | 61.84 | 0 | CTD_human, HPO, ORPHANET |
| PAX01 (C0023467) | Leukemia, Myelocytic, Acute | 20.33 | 1 | CTD_human |
| FOXO1 (C0022578) | Keratocnous | 20.11 | 1 | CTD_human |

Chimeric Protein-Protein Interactions



SNAPSHOTS OF PATIENTS' REPORTS

Cancer Predisposition Sequencing Reporter (CPSR)


Cancer predisposition gene is a term used to describe a gene that may increase a person's risk of developing some types of cancer if it has certain mutations (changes).

We are generating a CPSR for each patient. The CPSR is a computational workflow that interprets and classifies germline DNA variants identified from next-generation sequencing in the context of cancer predisposition and inherited cancer syndromes.

Variants classification

Pathogenic variant is a genetic alteration that increases an individual's susceptibility or predisposition to a certain disease or disorder. Variants are classified based on the pathogenicity into different classes ordered by highest pathogenicity:

- 1. Pathogenic Variants
- 2. Likely Pathogenic Variants
- 3. Variants of Uncertain Significance (VUS)
- 4. Likely Benign Variants
- 5. Benign Variants



Likely Pathogenic variant detected in one of SPCB patients

| SYMBOL | CLINVAR_PHENOTYPE | CONSEQUENCE | PROTEIN_CHANGE | GENOTYPE |
|--------|---|---|----------------|--------------|
| MUTYH | Colon cancer; Endometrial cancer; Hereditary cancer-predisposing syndrome; Neoplasm of stomach; Pilomatixoma; Breast carcinoma; Carcinoma of colon; Small intestine carcinoid; MYH-associated polyposis; Ovarian carcinoma; Colorectal adenomatous polyposis, autosomal recessive, with pilomatricomas; not specified; not provided | missense_variant, splice_region_variant | p.Gly368Asp | heterozygous |

Biomarkers


| | SYMBOL | GENE_NAME | CANCER_TYPE | CLINICAL_SIGNIFICANCE | EVIDENCE_LEVEL |
|---|--------|------------------------|-------------------|-----------------------|----------------------|
| 1 | SH2B3 | SH2B adaptor protein 3 | Colorectal Cancer | Positive | B: Clinical evidence |
| 2 | TP53 | tumor protein p53 | Breast Cancer | Positive | B: Clinical evidence |

GWAS Hits

| | SYMBOL | CONSEQUENCE | GWAS_CITATION | PROTEIN_CHANGE | GENOTYPE |
|---|--------|------------------|--|----------------|--------------|
| 1 | MTMR11 | missense_variant | Breast Carcinoma, Michailidou et al., 2017, Nature (association p-value =1.0e-14); Breast Carcinoma, Rashkin et al., 2020, Nat Commun (association p-value =5.0e-07) | p.Met159Val | heterozygous |
| 2 | CERS2 | missense_variant | Cancer, Brandes et al., 2021, Sci Rep (association p-value =2.0e-07) | p.Glu115Ala | heterozygous |
| 3 | R3HDM1 | missense_variant | Colorectal Cancer, Huyghe et al., 2021, Gut (association p-value =3.0e-08) | p.His544Arg | homozygous |
| 4 | TTN | missense_variant | Acute Myeloid Leukemia, Lv et al., 2016, Oncotarget (association p-value =2.0e-12); Acute Myeloid Leukemia, Lv et al., 2016, Oncotarget (association p-value =4.0e-07) | p.Val3261Met | homozygous |

SNAPSHOTS OF PATIENTS' REPORTS

Methylation Profiling Report



Supplier Information

Material type: NA
Gender: male Supplier diagnosis: CNS

Automatic Prediction

Array type: EPIC
Material type: DNA-FFPE
Gender: unknown

Legend

- ✓ Ok
- Supplier information or prediction not available
- ✗ Warning, mismatch of prediction and supplier information


Classification Match

Version 12.8 of the brain classifier results

| Methylation classes (Highest level >= 0.3, lower levels >= 0.1, all of lowest level) | | | | Calibrated score | Interpretation | |
|---|------------------------------------|-------------------------------------|--|------------------|----------------|---|
| Ependymal Tumours | | | | 0.99 | match | ✓ |
| | Posterior Fossa Ependymoma Group A | | | 0.99 | match | ✓ |
| | | Posterior Fossa Ependymoma Group A1 | | 0.99 | match | ✓ |
| | | | Mc Posterior Fossa Group A (pfa) Ependymoma, Subclass 1e (novel) | 0.97 | match | ✓ |
| | | | Mc Posterior Fossa Group A (pfa) Ependymoma, Subclass 1d (novel) | 0.01 | no match | ✗ |
| | | | Mc Posterior Fossa Group A (pfa) Ependymoma, Subclass 1c (novel) | 0.00 | no match | ✗ |
| | | | Mc Posterior Fossa Group A (pfa) Ependymoma, Subclass 1a (novel) | 0.00 | no match | ✗ |
| | | | Mc Posterior Fossa Group A (pfa) Ependymoma, Subclass 1b (novel) | 0.00 | no match | ✗ |
| | | | Mc Posterior Fossa Group A (pfa) Ependymoma, Subclass 1f (novel) | 0.00 | no match | ✗ |

Legend: ✓ Match (score >= 0.9) ✗ No match (score < 0.9): possibly still relevant for low tumor content and low DNA quality cases.

Copy Number Variation Profile



Depiction of chromosome 1 to 22 (and X/Y if automatic prediction was successful). Gains/amplifications represent positive, losses negative deviations from the baseline. 29 brain tumor relevant gene regions are highlighted for easier assessment. (see Hovestadt & Zapatka, <http://www.bioconductor.org/packages/devel/bioc/html/conumee.html>)

MGMT Promoto Status Prediction




| | | | |
|--------------|-----------|----------|----------|
| Status | Estimated | CI lower | CI upper |
| unmethylated | 0.06392 | 0.01208 | 0.27607 |


PUBLICATION

Our Recent Publication on Colon Cancer

In May 2023 our team published “**An integrated tumor, immune and microbiome atlas of colon cancer**” paper. DOI <https://doi.org/10.1038/s41591-023-02324-5>



Abstract: The lack of multi-omics cancer datasets with extensive follow-up information hinders the identification of accurate biomarkers of clinical outcome. In this cohort study, we performed comprehensive genomic analyses on fresh-frozen samples from 348 patients affected by primary colon cancer, encompassing RNA, whole-exome, deep T cell receptor and 16S bacterial rRNA gene sequencing on tumor and matched healthy colon tissue, complemented with tumor whole-genome sequencing for further microbiome characterization. A type 1 helper T cell, cytotoxic, gene expression signature, called Immunologic Constant of Rejection, captured the presence of clonally expanded, tumor-enriched T cell clones and outperformed conventional prognostic molecular biomarkers, such as the consensus molecular subtype and the microsatellite instability classifications. Quantification of genetic immunoediting, defined as a lower number of neoantigens than expected, further refined its prognostic value. We identified a microbiome signature, driven by *Ruminococcus bromii*, associated with a favorable outcome.



By combining microbiome signature and Immunologic Constant of Rejection, we developed and validated a composite score (mICRoScore), which identifies a group of patients with excellent survival probability. The publicly available multi-omics dataset provides a resource for better understanding colon cancer biology that could facilitate the discovery of personalized therapeutic approaches.

PATIENTS' INTERVIEWS

A Journey of Hope

When their two-year-old child was diagnosed with Burkitt's Lymphoma, the young parents felt their world shift beneath them. Desperate for answers and specialized care, they found themselves at the doors of Sidra Medicine.

The medical team at Sidra Medicine didn't just treat their child's illness; they embraced the family with warmth, professionalism, and a level of attentiveness that brought them comfort when they needed it most.

The days that followed were some of the hardest they had ever faced. Watching their little one endure diagnostic procedures and chemotherapy was a challenge they were not prepared for. Yet amid the difficult moments, the family found a lifeline.


The family was introduced to Sidra Medicine's Precision Oncology Initiative, a pioneering initiative focused on advancing cancer treatment, through cutting-edge research. This initiative involves the collection, storage, and use of tissue samples and health information to facilitate scientific studies. One of the key research methods used is whole genome sequencing (WGS), which enables researchers to analyze a child's genetic code in detail. While genetic alterations often occur only in tumors, identifying these changes can help oncologists tailor the child's treatment plan more effectively. In addition,

it provides valuable insights for researchers and physicians working to better understand the disease. After thorough analysis, the child's treating physician will receive a detailed report on the genetic alterations found in the tumor. This report is reviewed by a "molecular board" consisting of experts in oncology, pathology, genetics, and research, who advise the family on the findings and their implications for potential therapies. In the future, other researchers may request access to the biorepository to use the samples for further studies.

The family said: "We believe this research will be valuable and save others this ordeal."

When asked what message he would like to share with other families facing similar challenges, the family's response was heartfelt and full of hope: "Faith in God and His will, above all else. Sidra Medicine is highly professional and provides exceptional care to its patients. The care was excellent and exceeded our expectations."

For this family, Sidra Medicine wasn't just a hospital; it became a beacon of hope and a place where they could believe in a brighter future for their child. Their journey is a testament to the power of exceptional care, ground-breaking treatment protocols, and the belief that every small step forward matters.



Cancer Grant Awards

| No. | Grant Reference | Lead Principal Investigator | Title |
|-----|--|--|--|
| 1 | IRF22 (Internal Grants) | Dr. Wouter Hendrickx & Dr. Erdener Ozer | Pediatric solid tumor heterogeneity and clinical impact by multi-regional NGS @ Sidra Medicine |
| 2 | IRF22 (Internal Grants) | Dr. Wouter Hendrickx & Dr. Atta Maaz | Implementation of spatially resolved transcriptomics in pediatric brain tumors: toward advanced diagnostics enabling precision immunotherapeutic approaches. |
| 3 | IRF24 (Internal Grants) | Dr. Christophe Raynaud & Dr. Ayman Saleh | Prognostic and therapeutic potential of SLFN11 in Pediatric solid tumors |
| 4 | IRF24 (Internal Grants) | Dr. Erdener Ozer & Dr. Wouter Hendrickx | Integrative application of high-resolution Single-cell ATAC and RNA sequencing in clinical decision-making of neuroblastoma patients |
| 5 | NPRP10-0129-170277 (External – QNRF) | Dr. Cristina Maccalli | Mapping genotype to phenotype for breast and colorectal cancer stem cells: Implications and perspectives in cancer therapy |
| 6 | NPRP11S-0121-18035 1 (External – QNRF) | Dr. Davide Bedognetti | Towards personalize cancer medicine: Immunoscore and immunogenomic score in primary and metastatic colorectal cancer patients from Europe and Qatar. |
| 7 | NPRP13S-0107-20002 3 (External – QNRF) | Dr. Sara Deola | Mapping the road of GVHD and GVT. Multicenter Prospective Study of the "Transcriptome Fingerprinting" Post Allogeneic Hematopoietic Stem Cell Transplantation Using System Immunology Approach |
| 8 | PPM 04-0128-200014 (External – QNRF) | Dr. Naima Al-Mulla | Pharmacogenetics in childhood acute lymphoblastic leukemia: from variants identification to clinical implementation. |
| 9 | PPM 05-0316-210001 (External – QNRF) | Dr. Wouter Hendrickx | Multiregional genomic sequencing of pediatric cancer patients from Qatar, solid tumor heterogeneity and clinical impact. |
| 10 | ARG01-0507-230085 (External – QNRF) | Dr. Wouter Hendrickx | Recapitulation of the human microbiome risk score in mice to elucidate its mechanism of action. |

Publication List (2021- 2023)

| PEDIATRIC CANCER | |
|---|--|
| Shimaa Sherif, Wouter R. L. Hendrickx, Christophe Michel Raynaud, William Mifsud, Davide Bedognetti, Ata Ur Rehman Maaz Identification of an unusual combination of actionable mutations through genomic profiling in a child with an aggressive sarcoma PEDIATRIC BLOOD & CANCER, 2023 PMID: 37845795 | Denize T, Massa S, Valent A, Militti L, Bertolotti A, Barisella M, Rioux-Leclercq N, Malouf GG, Spreafico F, Verschuur A, van der Beek J, Tytgat L, van den Heuvel-Eibrink MM, Vujanic G, Collini P, Coulomb A. Renal cell carcinoma in children and adolescents: a retrospective study of a French-Italian series of 93 cases Histopathology, 2022 PMID35238063 |
| Muhammad Saghir Khan , Ata Ur Rehman Maaz , Abid Quddus Qazi , Sophia Aslam, Shazia Riaz , Ayesha Saeed Malik , Najma Shaheen Prognostic impact of pre-referral tumor resection in unilateral Wilms tumor: A single-institute experience from a lower middle-income country PEDIATRIC BLOOD & CANCER, 2023 PMID: 37962283 | Jackson TJ, Brisse HJ, Pritchard-Jones K, Nakata K, Morosi C, Oue T, Irtan S, Vujanic G, van den Heuvel-Eibrink MM, Graf N, Chowdhury T; SIOP RTSG Biopsy Working Group. How we approach paediatric renal tumour core needle biopsy in the setting of preoperative chemotherapy: A Review from the SIOP Renal Tumour Study Group Pediatric Blood & Cancer, 2022 PMID35587187 |
| Felix K F Kommos , Anne-Sophie Chong , Maria Apellaniz-Ruiz , Gulisa Turashvili , Kay J Park , Krisztina Hanley , Elvis Terci Valera , Andreas von Deimling, Gordan Vujanic, W Glenn McCluggage, William D Foulkes Teratoma-associated and so-called pure Wilms tumour of the ovary represent two separate tumour types with distinct molecular features. HISTOPATHOLOGY, 2023 PMID: 38084641 | Khan MR, Maaz AUR, Ashraf MS. Challenges in the Management of Wilms Tumor in a Developing Country: A Twenty Years’ Experience From a Single Center in Pakistan Journal Of Pediatric Hematology Oncology, 2022 PMID35917164 |
| Ellen D'Hooghe, Rhoikos Furtwängler, Tanzina Chowdhury, Christian Vokuhl, Reem Al-Saadi, Kathy Pritchard-Jones, Norbert Graf, Gordan M Vujanić Stage I epithelial or stromal type Wilms tumors are low risk tumors: An analysis of patients treated on the SIOP-WT-2001 protocol in the UK-CCLG and GPOH studies (2001-2020). Cancer, 2023 PMID: 36929497 | Abdelhafeez AH, Reljic T, Kumar A, Banu T, Cox S, Davidoff AM, Elgendy A, Ghandour K, Gerstle JT, Karpelowsky J, Kaste SC, Kechiche N, Esiashvili N, Nasir A, Ngongola A, Marollano J, Moreno AA, Muzira A, Parkes J, Saldaña LJ, Shalkow J, Vujanić GM, Velasquez T, Lakhoo K, Mukkada S, Abib S. Evidence-based surgical guidelines for treating children with Wilms tumor in low-resource settings Pediatric Blood & Cancer, 2022 PMID35929184 |
| Shimaa Sherif, Jessica Roelands, William Mifsud, Eiman I Ahmed, Christophe M Raynaud, Darawan Rinchai, Abbirami Sathappan, Ata Maaz, Ayman Saleh, Erdener Ozer, Khalid A Fakhro, Borbala Mifsud, Vésteinn Thorsson, Davide Bedognetti, Wouter R L Hendrickx The immune landscape of solid pediatric tumors Journal Of Experimental & Clinical Cancer Research, 2022 PMID35690832 | Kuttikrishnan S, Bhat AA, Mateo JM, Ahmad F, Alali FQ, El-Elimat T, Oberlies NH, Pearce CJ, Uddin S. Anticancer activity of Neosetophomone B by targeting AKT/ SKP2/MTH1 axis in leukemic cells Biochemical And Biophysical Research Communications, 2022 PMID35228122 |
| Vujanić GM, Mifsud W, Chowdhury T, Al-Saadi R, Pritchard-Jones K; Renal Tumour Special Interest Group of the Children’s Cancer and Leukaemia Group. Characteristics and outcomes of preoperatively treated patients with anaplastic Wilms tumors registered in the UK SIOP-WT-2001 and IMPORT study cohorts (2002-2020) Cancer, 2022 PMID35119702 | van der Beek JN, Hol JA, Coulomb-l’Hermine A, Graf N, van Tinteren H, Pritchard-Jones K, Houwing ME, de Krijger RR, Vujanic GM, Dzhuma K, Schenk JP, Littooij AS, Ramírez-Villar GL, Murphy D, Ray S, Al-Saadi R, Gessler M, Godzinski J, Ruebe C, Collini P, Verschuur AC, Frisk T, Vokuhl C, Hulsbergen-van de Kaa CA, de Camargo B, Sandstedt B, Selle B, Tytgat GAM, van den Heuvel-Eibrink MM, Characteristics and outcome of pediatric renal cell carcinoma patients registered in the International Society of Pediatric Oncology (SIOP) 93-01, 2001 and UK-IMPORT database: A report of the SIOP-Renal Tumor Study Group. International Journal Of Cancer, 2021 PMID33460450 |
| Mifsud W, Furtwängler R, Vokuhl C, D’Hooghe E, Pritchard-Jones K, Graf N, Vujanić GM. Treatment of patients with stage I focal anaplastic and diffuse anaplastic Wilms tumour: A report from the SIOP-WT-2001 GPOH and UK-CCLG studies European Journal Of Cancer, 2022 PMID35255331 | Dzhuma K, Powis M, Vujanic G, Watson T, Olsen O, Shelmerdine S, Oostveen M, Brok J, Irtan S, Williams R, Tugnait S, Smeulders N, Mushtaq I, Chowdhury T, Al-Saadi R, Pritchard-Jones K. Surgical management, staging, and outcomes of Wilms tumours with intravascular extension: Results of the IMPORT study Journal Of Pediatric Surgery, 2021 PMID34565577 |
| Vujanić GM, Parsons LN, D’Hooghe E, Treece AL, Collini P, Perlman EJ. Pathology of Wilms’ tumour in International Society of Paediatric Oncology (SIOP) and Children’s oncology group (COG) renal tumour studies: Similarities and differences Histopathology, 2022 PMID35275409 | Spreafico F, Fernandez CV, Brok J, Nakata K, Vujanic G, Geller JI, Gessler M, Maschietto M, Behjati S, Polanco A, Paintsil V, Luna-Fineman S, Pritchard-Jones K. Wilms tumour Nature Reviews Disease Primers, 2021 PMID34650095 |
| Kuttikrishnan S, Masoodi T, Sher G, Bhat AA, Patil K, El-Elimat T, Oberlies NH, Pearce CJ, Haris M, Ahmad A, Alali FQ, Uddin S. Bioinformatics Analysis Reveals FOXM1/BUB1B Signaling Pathway as a Key Target of Neosetophomone B in Human Leukemic Cells: A Gene Network-Based Microarray Analysis Frontiers In Oncology, 2022 PMID35847923 | Nakata K, Williams R, Kinoshita Y, Koshinaga T, Moroz V, Al-Saadi R, Vujanic G, Oue T, Pritchard-Jones K, Comparative analysis of the clinical characteristics and outcomes of patients with Wilms tumor in the United Kingdom and Japan. Pediatric Blood & Cancer, 2021 PMID34056846. |

CANCER IMMUNOLOGY & IMMUNOTHERAPY

Alice Mogenet, Pascal Finetti , Emilie Denicolai , Laurent Greillier , Pascaline Boudou-Rouquette , François Goldwasser , Gwenael Lumet , Michele Ceccarelli , Daniel Birnbaum , Davide Bedognetti, Emilie Mamessier , Fabrice Barlesi, François Bertucci , Pascale Tomasini
Immunologic constant of rejection as a predictive biomarker of immune checkpoint inhibitors efficacy in non-small cell lung cancer.
Journal of Translational Medicine, 2023
PMID: 37726776

Teresa Maria Rosaria Noviello , Anna Maria Di Giacomo, Francesca Pia Caruso, Alessia Covre, Roberta Mortarini , Giovanni Scala , Maria Claudia Costa , Sandra Coral , Wolf H Fridman , Catherine Sautès-Fridman , Silvia Brich , Giancarlo Prunerì , Elena Simonetti , Maria Fortunata Lofiego 3, Rossella Tufano 2 13, Davide Bedognetti 14 15, Andrea Anichini , Michele Maio , Michele Ceccarelli
Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and integrated multi-omic analysis in the phase 1b NIBIT-M4 trial.
Nature Communications, 2023
PMID: 37739939

Yufeng Wang , David L Drum , Ruochuan Sun, Yida Zhang, Feng Chen , Fengfei Sun , Emre Dal , Ling Yu , Jingyu Jia , Shahrzad Arya , Lin Jia , Song Fan , Steven J Isakoff , Allison M Kehlmann , Gianpietro Dotti , Fubao Liu , Hui Zheng , Cristina R Ferrone , Alphonse G Taghian , Albert B DeLeo , Marco Ventin , Giulia Cattaneo , Yongxiang Li , Youssef Jounaidi, Peigen Huang , Cristina Maccalli , Hanyu Zhang , Cheng Wang , Jibing Yang , Genevieve M Boland , Ruslan I Sadreyev, LaiPing Wong , Soldano Ferrone, Xinhui Wang
Stressed target cancer cells drive nongenetic reprogramming of CAR T cells and solid tumor microenvironment.
Nature Communications, 2023
PMID: 37714830

Laura Fusco, Arianna Gazzi, Christopher E Shuck, Marco Orecchioni, Eiman I Ahmed, Linda Giro, Barbara Zavan, Açelya Yilmazer , Klaus Ley, Davide Bedognetti , Yury Gogotsi , Lucia Gemma Delogu
V4 C3 MXene Immune Profiling and Modulation of T Cell-Dendritic Cell Function and Interaction.
Small Methods, 2023
PMID: 37291737

Tomei S, Ibnaof O, Ravindran S, Ferrone S, Maccalli C.
Cancer Stem Cells Are Possible Key Players in Regulating Anti-Tumor Immune Responses: The Role of Immunomodulating Molecules and MicroRNAs.
Cancers (Basel), Cancers, 2021
PMID33918136

Karama Makni Maalej, Maysaloun Merhi, Varghese P Inchakalody , Sarra Mestiri , Majid Alam, Cristina Maccalli, Honar Cherif, Shahab Uddin, Martin Steinhoff, Francesco M Marincola, Said Dermime.
CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances.
Molecular Cancer, 2023
PMID: 36717905

Sherif S, Mall R, Almeer H, Naik A, Al Homaid A, Thomas R, Roelands J, Narayanan S, Mohamed MG, Bedri S, Al-Bader SB, Junejo K, Bedognetti D, Hendrickx W, Decock J.
Immune-related 3-lncRNA signature with prognostic connotation in a multi-cancer setting
Journal Of Translational Medicine, 2022
PMID36180904

Bertucci F, Niziers V, de Nonneville A, Finetti P, Mescam L, Mir O, Italiano A, Le Cesne A, Blay JY, Ceccarelli M, Bedognetti D, Birnbaum D, Mamessier E.
Immunologic constant of rejection signature is prognostic in soft-tissue sarcoma and refines the CINSARC signature
Journal For Immunotherapy Of Cancer, 2022
PMID35017155

Jessica Roelands, Davide Bedognetti.
Analytic pipelines to assess the relationship between immune response and germline genetics in human tumors.
STAR Protocols, 2022
PMID36595917

Turan T, Kongpachith S, Halliwill K, Roelands J, Hendrickx W, Marincola FM, Hudson TJ, Jacob HJ, Bedognetti D, Samayoa J, Ceccarelli M.
A balance score between immune stimulatory and suppressive microenvironments identifies mediators of tumour immunity and predicts pan-cancer survival
British Journal Of Cancer, 2021
PMID33277603

Naik A, Thomas R, Al-Khadairi G, Bacha R, Hendrickx W, Decock J.
Cancer testis antigen PRAME: An anti-cancer target with immunomodulatory potential.
Journal Of Cellular And Molecular Medicine, 2021
PMID34612587

Giovanni Fucà, Francesca Ligorio, Veronica Huber, Andrea Vingiani, Darawan Rinchai, Alessandra Raimondi, Fabio Iannelli, Gianmaria Frigè, Antonino Belfiore, Luca Lalli, Claudia Chiodoni, Valeria Cancila, Federica Zanardi, Arta Ajazi, Salvatore Cortellino, Viviana Vallacchi, Paola Squarcina, Agata Cova, Samantha Pesce, Paola Frati, Raghvendra Mall, Paola Antonia Corsetto, Angela Maria Rizzo, Cristina Ferraris, Secondo Folli, Marina Chiara Garassino, Giuseppe Capri, Giulia Bianchi, Mario P. Colombo, Saverio Minucci, Marco Foiani, Valter Longo, Giovanni Apolone, Valter Torri, Giancarlo Prunerì, Davide Bedognetti, Licia Rivoltini, Filippo de Braud
Fasting-mimicking diet is safe and reshapes metabolism and antitumor immunity in cancer patients
Cancer Discovery, 2021
PMID34789537

Guerrouahen B, Elnaggar M, Al-Mohannadi A, Kizhakayil D, Bonini C, Benjamin R, Brentjens R, Buchholz CJ, Casorati G, Ferrone S, Locke FL, Martin F, Schambach A, Turtle C, Veys P, van der Vliet HJ, Maccalli C; EICCI Faculty Group.
Proceedings From the First International Workshop at Sidra Medicine: “Engineered Immune Cells in Cancer Immunotherapy (EICCI): From Discovery to Off-the-Shelf Development”, 15(th)-16(th) February 2019, Doha, Qatar
Frontiers In Immunology, 2021
PMID33584653

Lone SN, Bhat AA, Wani NA, Karedath T, Hashem S, Nisar S, Singh M, Bagga P, Das BC, Bedognetti D, Reddy R, Frenneaux MP, El-Rifai W, Siddiqi MA, Haris M, Macha MA,
miRNAs as novel immunoregulators in cancer.
Seminars In Cell And Developmental Biology, 2021
PMID33926791

CNS CANCER

Omar Tluli , Mazyona Al-Maadhadi , Aisha Abdulla Al-Khulaifi , Aishat F Akomolafe , Shaikha Y Al-Kuwari , Roudha Al-Khayarin , Cristina Maccalli , Shona Pedersen
Exploring the Role of microRNAs in Glioma Progression, Prognosis, and Therapeutic Strategies.
Cancers, 2023
PMID: 37686489

Chawla S, Bukhari S, Afridi OM, Wang S, Yadav SK, Akbari H, Verma G, Nath K, Haris M, Bagley S, Davatzikos C, Loevner LA, Mohan S.
Metabolic and physiologic magnetic resonance imaging in distinguishing true progression from pseudoprogression in patients with glioblastoma
Nmr In Biomedicine, 2022
PMID35233862

Tomei S, Volontè A, Ravindran S, Mazzoleni S, Wang E, Galli R, Maccalli C,
MicroRNA Expression Profile Distinguishes Glioblastoma Stem Cells from Differentiated Tumor Cells.
Journal Of Personalized Medicine, 2021
PMID33916317

Caruso FP, Garofano L, D’Angelo F, Yu K, Tang F, Yuan J, Zhang J, Cerulo L, Pagnotta SM, Bedognetti D, Sims PA, Suvà M, Su XD, Lasorella A, Iavarone A, Ceccarelli M,
A map of tumor-host interactions in glioma at single-cell resolution.
Gigascience, 2020
PMID33155039

BREAST CANCER

Christophe Michel Raynaud , Eiman I Ahmed, Ayesha Jabeen , Apryl Sanchez , Shimaa Sherif , Tatiana C Carneiro-Lobo , Amany Awad , Dina Awartani , Adviti Naik , Remy Thomas , Julie Decock , Gabriele Zoppoli , Davide Bedongnetti, Wouter R L Hendrickx
Modulation of SLFN11 induces changes in DNA Damage response in breast cancer.
Cancer Cell International, 2023
PMID: 38001424

Aya Abunada , Zaid Sirhan, Anita Thyagarajan, Ravi P Sahu
Tyrosine kinase inhibitors and human epidermal growth factor receptor-2 positive breast cancer
World Journal of Clinical Oncology 2023
PMID: 37275938

Mehraj U, Alshehri B, Khan AA, Bhat AA, Bagga P, Wani NA, Mir MA.
Expression Pattern and Prognostic Significance of Chemokines in Breast cancer: An Integrated Bioinformatics Analysis
Clinical Breast Cancer, 2022
PMID35585016

Cirmena G, Ferrando L, Ravera F, Garuti A, Dameri M, Gallo M, Barbero V, Ferrando F, Del Mastro L, Garlaschi A, Friedman D, Fregatti P, Ballestrero A, Zoppoli G.
Plasma Cell-Free DNA Integrity Assessed by Automated Electrophoresis Predicts the Achievement of Pathologic Complete Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer
Jco Precision Oncology, 2022
PMID34768233

Kannan S, Shailesh H, Mohamed H, Souchelnytskyi N, Souchelnytskyi S.
A long-term 10G-hypergravity exposure promotes cell-cell contacts and reduces adhesiveness to a substrate, migration, and invasiveness of MCF-7 human breast cancer cells.
2022
PMID35548967

Pullikuth AK, Routh ED, Zimmerman KD, Chifman J, Chou JW, Soike MH, Jin G, Su J, Song Q, Black MA, Print C, Bedognetti D, Howard-McNatt M, O’Neill SS, Thomas A, Langefeld CD, Sigalov AB, Lu Y, Miller LD.
Bulk and Single-Cell Profiling of Breast Tumors Identifies TREM-1 as a Dominant Immune Suppressive Marker Associated With Poor Outcomes
Frontiers In Oncology, 2021
PMID34956864

Mehraj U, Ganai RA, Macha MA, Hamid A, Zargar MA, Bhat AA, Nasser MW, Haris M, Batra SK, Alshehri B, Al-Baradie RS, Mir MA, Wani NA,
The tumor microenvironment as driver of stemness and therapeutic resistance in breast cancer: New challenges and therapeutic opportunities.
Cellular Oncology, 2021
PMID34528143

Therachiyil L, Anand A, Azmi A, Bhat A, Korashy HM, Uddin S.
Role of RAS signaling in ovarian cancer
F100 Research, F1000 Research, 2022
PMID36451660

Al-Farsi H, Al-Azwani I, Malek JA, Chouchane L, Rafii A, Halabi NM.
Discovery of new therapeutic targets in ovarian cancer through identifying significantly non-mutated genes
Journal Of Translational Medicine, 2022
PMID35619151

Tarang Sharma, Sabah Nisar, Tariq Masoodi, Muzafar A Macha, Shahab Uddin, Ammira Al-Shabeeb Akil, Tej K Pandita, Mayank Singh, Ajaz A Bhat.
Current and emerging biomarkers in ovarian cancer diagnosis; CA125 and beyond.
Advances in Protein Chemistry and Structural Biology, 2022
PMID36707207

Winkler C, King M, Berthe J, Ferraioli D, Garuti A, Grillo F, Rodriguez-Canales J, Ferrando L, Chopin N, Ray-Coquard I, Delpuech O, Bedognetti D, Ballestrero A, Leo E, Zoppoli G,
SLFN11 captures cancer-immunity interactions associated with platinum sensitivity in high-grade serous ovarian cancer.
Jci Insight, 2021
PMID34549724

De Sanctis V, Ahmed S, Soliman A, Alyafei F, Alaaraj N, Al Maadheed M, Clelland C.
A rare case of Ovarian Juvenile Granulosa Cell Tumor in an Infant with Isosexual Pseudo Puberty and a Revision of Literature
Acta Biomedica, 2021
PMID34487069

OTHER CANCERS

Jessica Roelands, Peter J K Kuppen , Eiman I Ahmed , Raghvendra Mall , Tariq Masoodi , Parul Singh, Gianni Monaco , Christophe Raynaud , Noel F C C de Miranda , Luigi Ferraro , Tatiana C Carneiro-Lobo, Najeeb Syed, Arun Rawat, Amany Awad, Julie Decock , William Mifsud, Lance D Miller, Shimaa Sherif, Mahmoud G Mohamed, Darawan Rinchai , Marc Van den Eynde, Rosalyn W Sayaman, Elad Ziv, Francois Bertucci , Mahir Abdulla Petkar, Stephan Lorenz , Lisa Sara Mathew , Kun Wang, Selvasankar Murugesan, Damien Chaussabel, Alexander L Vahrmeijer, Ena Wang, Anna Ceccarelli , Khalid A Fakhro, Gabriele Zoppoli, Alberto Ballestrero , Rob A E M Tollenaar, Francesco M Marincola, Jérôme Galon, Souhaila Al Khodor, Michele Ceccarelli, Wouter Hendrickx, Davide Bedognetti
An integrated tumor, immune and microbiome atlas of colon cancer.
Nature Medicine, 2023
PMID: 37202560

Nassiba Taib, Maysaloun Merhi, Varghese Inchakalody , Sarra Mestiri , Shereena Hydrose, Karama Makni-Maalej, Afsheen Raza, Fairooz Sahir, Fouad Azizi, Parveen B Nizamuddin, Queenie Fernandes, Zeenath Safira K M Yoosuf, Salam Almoghribi, Lobna Al-Zaidan, Alaaeldin Shablak, Shahab Uddin, Cristina Maccalli , Mohammed Ussama Al Homsy, Said Dermime.
Treatment with decitabine induces the expression of stemness markers, PD-L1 and NY-ESO-1 in colorectal cancer: potential for combined chemioimmunotherapy.
Journal of Translational Medicine, 2023
PMID: 37004094

Sakib Mahmud, Tariq O Abbas, Adam Mushtak, Johayra Prithula 6, Muhammad E H Chowdhury
Kidney Cancer Diagnosis and Surgery Selection by Machine Learning from CT Scans Combined with Clinical Metadata
Cancers 2023,
PMID: 37370799

Srirangam Nadhamuni V, Iacovazzo D, Evanson J, Sahdev A, Trouillas J, McAndrew L, R Kurzawinski T, Bryant D, Hussain K, Bhattacharya S, Korbonits M.
GHRH secretion from a pancreatic neuroendocrine tumor causing gigantism in a patient with MEN1.
Endocrinology, Diabetes & Metabolism Case Reports, 2021
PMID34156350

Gh Rasool Bhat , Rajeshwer Singh Jamwal , Itty Sethi , Amrita Bhat , Ruchi Shah , Sonali Verma , Minerva Sharma , Hana Q Sadida , Sara K Al-Marzooqi , Tariq Masoodi, Sameer Mirza , Mohammad Haris , Muzafar A Macha , Ammira S Alshabeeb Akil, Ajaz A Bhat , Rakesh Kumar
Associations between telomere attrition, genetic variants in telomere maintenance genes, and non-small cell lung cancer risk in the Jammu and Kashmir population of North India
BMC CANCER, 2023
PMID: 37718447

Djekidel M, Syed G, Kanbour A.
Imaging Biomarkers in Lung Cancer with (68)Ga-DOTATATE, (18)F-Fluoride, and (18)F-FDG PET-CT Scans and The Theranostics Paradigm.
Journal Of Nuclear Medicine, 2021
PMID33722922

Amal Kassab, Ishita Gupta, Ala-Eddin Al Moustafa
Role of E2F transcription factor in oral cancer: Recent insight and advancements.
SEMINARS IN CANCER BIOLOGY 2023
PMID: 36924812

Nisar S, Yousuf P, Masoodi T, Wani NA, Hashem S, Singh M, Sageena G, Mishra D, Kumar R, Haris M, Bhat AA, Macha MA.
Chemokine-Cytokine Networks in the Head and Neck Tumor Microenvironment.
International Journal Of Molecular Sciences, 2021
PMID33925575

Macha MA, Wani NA, Ganai RA, Bhat AA, Hamid A, Hashem S, Haris M, Chauhan SS, Zargar MA, Batra SK. **Recent Advances in Head and Neck Tumor Microenvironment-Based Therapy.** Advances In Experimental Medicine And Biology, 2021 PMID34185284

Bhat AA, Yousuf P, Wani NA, Rizwan A, Chauhan SS, Siddiqi MA, Bedognetti D, El-Rifai W, Frenneaux MP, Batra SK, Haris M, Macha MA. **Tumor microenvironment: an evil nexus promoting aggressive head and neck squamous cell carcinoma and avenue for targeted therapy.** Signal Transduction And Targeted Therapy, 2021 PMID33436555

Sharma T, Gupta A, Chauhan R, Bhat AA, Nisar S, Hashem S, Akhtar S, Ahmad A, Haris M, Singh M, Uddin S. **Cross-talk between the microbiome and chronic inflammation in esophageal cancer: potential driver of oncogenesis.** 2022 PMID35511379

Singh HM, Leber MF, Bossow S, Engeland CE, Dessila J, Grossardt C, Zaoui K, Bell JC, Jäger D, von Kalle C, Ungerechts G. **MicroRNA-sensitive oncolytic measles virus for chemovirotherapy of pancreatic cancer.** Molecular Therapy Oncolytics, 2021 PMID34141871

Scatena C, Murtas D, Tomei S. **Cutaneous Melanoma Classification: The Importance of High-Throughput Genomic Technologies.** Frontiers In Oncology, 2021 PMID34123788

CANCER BIOLOGY AND THERAPY

Gunjan Dagar , Ashna Gupta , Tariq Masoodi, Sabah Nisar, Maysaloun Merhi, Sheema Hashem , Ravi Chauhan , Manisha Dagar , Sameer Mirza, Puneet Bagga , Rakesh Kumar, Ammira S Al-Shabeeb Akil, Muzafar A Macha, Mohammad Haris, Shahab Uddin, Mayank Singh, Ajaz A Bhat. **Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments.** Journal of Translational Medicine 2023 PMID: 37420216

Nouha Abdelaziz, Lubna Therachiyil, Hana Q Sadida, Ateeque Mohamed Ali, Omar S Khan , Mayank Singh , Abdul Q Khan , Ammira S Al-Shabeeb Akil , Ajaz A Bhat , Shahab Uddin **Epigenetic inhibitors and their role in cancer therapy.** International Review of Cell and Molecular Biology 2023 PMID: 37657859

Gowtham Kumar Subbaraj, Tariq Masoodi, Santhosh Kumar Yasam, Kirubhanand Chandrashekar, Langeswaran Kulanthaivel, Noor Ahmad Shaik, Sheema Hashem, Ammira S Alshabeeb Akil, Ajaz A Bhat **Anti-angiogenic effect of nano-formulated water soluble kaempferol and combretastatin in an in vivo chick chorioallantoic membrane model and HUVEC cells.** BIOMEDICINE & PHARMACOTHERAPY, 2023 PMID: 37141736

Maryam Farzaneh , Ava Nasrolahi, Farhoodeh Ghaedrahmati, Tariq Masoodi, Sajad Najafi, Mohadeseh Sheykhi-Sabzehpoush, Mahrokh Abouali Gale Dari , Klaudia Radoszkiewicz , Shahab Uddin , Shirin Azizidoost, Seyed Esmaeil Khoshnam **Potential roles of lncRNA-XIST/miRNAs/mRNAs in human cancer cells.** Clinical & Translational Oncology, 2023 PMID: 6853400

Anas Hamad, Shereen Elazzazy, Salha Bujassoum, Kakil Rasul, Javid Gaziev, Honar Cherif , Zakiya Al-Boloshi, Yolande Hanssens, Ayman Saleh, Hadi Abu Rasheed, Daoud Al-Badriyeh, Ahmed Babiker, Amid Abu Hmaidan, Moza Al-Hail **Applying value-based strategies to accelerate access to novel cancer medications: guidance from the Oncology Health Economics Expert Panel in Qatar (Q-OHEP).** BMC HEALTH SERVICES RESEARCH, 2023 PMID: 36609388

Jehan AlRayahi, Osamah Alwalid, Walid Mubarak, Ata Ur Rehman Maaz, William Mifsud **Pediatric Brain Tumors in the Molecular Era: Updates for the Radiologist.** SEMINARS IN ROENTGENOLOGY, 2023 PMID: 36732011

Graeme Ewan Glass **Photobiomodulation: A Systematic Review of the Oncologic Safety of Low-Level Light Therapy for Aesthetic Skin Rejuvenation.** Aesthetic Surgery Journal, 2023 PMID: 36722207

Tomas Venit , Oscar Sapkota , Wael Said Abdrabou, Palanikumar Loganathan , Renu Pasricha , Syed Raza Mahmood , Nadine Hosny El Said, Shimaa Sherif , Sneha Thomas , Salah Abdelrazig , Shady Amin , Davide Bedognetti , Youssef Idaghdour , Mazin Magzoub , Piergiorgio Percipalle **Positive regulation of oxidative phosphorylation by nuclear myosin 1 protects cells from metabolic reprogramming and tumorigenesis in mice.** Nature Communications, 2023 PMID: 37816864

Shilpa Kuttikrishnan, Tariq Masoodi, Fareed Ahmad, Gulab Sher, Kirti S Prabhu, Jericha M Mateo, Joerg Buddenkotte, Tamam El-Elimat, Nicholas H Oberlies, Cedric J Pearce, Ajaz A Bhat, Feras Q Alali, Martin Steinhoff , Shahab Uddin **In vitro evaluation of Neosetophomone B inducing apoptosis in cutaneous T cell lymphoma by targeting the FOXM1 signaling pathway.** JOURNAL OF DERMATOLOGICAL SCIENCE, 2023 PMID: 7865581

Shilpa Kuttikrishnan , Fareed Ahmad , Jericha M Mateo , Kirti S Prabhu , Tamam EL-Elimat , Nicholas H Oberlies , Cedric J Pearce , Ammira S Alshabeeb Akil, Ajaz A Bhat , Feras Q Alali , Shahab Uddin **Neosetophomone B induces apoptosis in multiple myeloma cells via targeting of AKT/SKP2 signaling pathway.** CELL BIOLOGY INTERNATIONAL, 2023 PMID: 37885161

Abhinava K Mishra , Ashna Gupta, Gunjan Dagar, Dayasagar Das, Abhijit Chakraborty , Shabirul Haque , Chandra Prakash Prasad , Archana Singh , Ajaz A Bhat , Muzafar A Macha , Moez Benali , Kamal S Saini, Rebecca Ann Previs , Deepak Saini, Dwaipayan Saha , Preyangsee Dutta , Aseem Rai Bhatnagar, Mrinalini Darswal, Abhishek Shankar, Mayank Singh **CAR-T-Cell Therapy in Multiple Myeloma: B-Cell Maturation** Antigen (BCMA) and Beyond Vaccines 2023 PMID: 38006053

Queenie Fernandes , Lubna Therachiyil , Abdul Q Khan , Takwa Bedhiafi , Hesham M Korashy , Ajaz A Bhat , Shahab Uddin **Shrinking the battlefield in cancer therapy: Nanotechnology against cancer stem cells.** EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2023 PMID: 37729956

Nisar S, Masoodi T, Prabhu KS, Kuttikrishnan S, Zarif L, Khatoon S, Ali S, Uddin S, Akil AA, Singh M, Macha MA, Bhat AA. **Natural products as chemo-radiation therapy sensitizers in cancers.** Biomedicine & Pharmacotherapy, 2022 PMID36030591

Hashem S, Ali TA, Akhtar S, Nisar S, Sageena G, Ali S, Al-Mannai S, Therachiyil L, Mir R, Elfaki I, Mir MM, Jamal F, Masoodi T, Uddin S, Singh M, Haris M, Macha M, Bhat AA. **Targeting cancer signaling pathways by natural products: Exploring promising anti-cancer agents.** Biomedicine & Pharmacotherapy, 2022 PMID35658225

Bhat AA, Nisar S, Mukherjee S, Saha N, Yarravarapu N, Lone SN, Masoodi T, Chauhan R, Maacha S, Bagga P, Dhawan P, Akil AA, El-Rifai W, Uddin S, Reddy R, Singh M, Macha MA, Haris M. **Integration of CRISPR/Cas9 with artificial intelligence for improved cancer therapeutics.** Journal Of Translational Medicine, 2022 PMID36401282

Lone SN, Nisar S, Masoodi T, Singh M, Rizwan A, Hashem S, El-Rifai W, Bedognetti D, Batra SK, Haris M, Bhat AA, Macha MA. **Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments.** Molecular Cancer, 2022 PMID35303879

Sher G, Masoodi T, Patil K, Akhtar S, Kuttikrishnan S, Ahmad A, Uddin S.
Dysregulated FOXM1 signaling in the regulation of cancer stem cells.
Seminars In Cancer Biology, 2022
PMID35931301

Gritti I, Basso V, Rinchai D, Corigliano F, Pivetti S, Gaviraghi M, Rosano D, Mazza D, Barozzi S, Roncador M, Parmigiani G, Legube G, Parazzoli D, Cittaro D, Bedognetti D, Mondino A, Segalla S, Tonon G.
Loss of ribonuclease DIS3 hampers genome integrity in myeloma by disrupting DNA:RNA hybrid metabolism.
Embo Journal, 2022
PMID36215697

Lévy R, Langlais D, Béziat V, Rapaport F, Rao G, Lazarov T, Bourgey M, Zhou YJ, Briand C, Moriya K, Ailal F, Avery DT, Markle J, Lim AI, Ogishi M, Yang R, Pelham S, Emam M, Migaud M, Deswarte C, Habib T, Saraiva LR, Moussa EA, Guennoun A, Boisson B, Belkaya S, Martinez-Barricarte R, Rosain J, Belkadi A, Breton S, Payne K, Benhsaien I, Plebani A, Lougaris V, Di Santo JP, Neven B, Abel L, Ma CS, Bousfiha AA, Marr N, Bustamante J, Liu K, Gros P, Geissmann F, Tangye SG, Casanova JL, Puel A.
Inherited human c-Rel deficiency disrupts myeloid and lymphoid immunity to multiple infectious agents.
Journal Of Clinical Investigation, 2021
PMID34623332

Karedath T, Al-Dasim FM, Ahmed I, Al-Qurashi A, Raza A, Andrews SS, Ahmed AA, Ali Mohamoud Y, Dermime S, Malek JA.
Regulation of Circular RNA CircNFATC3 in Cancer Cells Alters Proliferation, Migration, and Oxidative Phosphorylation.
Frontiers In Cell And Developmental Biology, 2021
PMID33816459

Sukumaran P, Nascimento Da Conceicao V, Sun Y, Ahamad N, Saraiva LR, Selvaraj S, Singh BB.
Calcium Signaling Regulates Autophagy and Apoptosis.
Cells, 2021
PMID34440894

Nisar S, Bhat AA, Singh M, Karedath T, Rizwan A, Hashem S, Bagga P, Reddy R, Jamal F, Uddin S, Chand G, Bedognetti D, El-Rifai W, Frenneaux MP, Macha MA, Ahmed I, Haris M.
Insights Into the Role of CircRNAs: Biogenesis, Characterization, Functional, and Clinical Impact in Human Malignancies.
Frontiers In Cell And Developmental Biology, 2021
PMID33614648

Chauhan R, Bhat AA, Masoodi T, Bagga P, Reddy R, Gupta A, Sheikh ZA, Macha MA, Haris M, Singh M.
Ubiquitin-specific peptidase 37: an important cog in the oncogenic machinery of cancerous cells.
Journal Of Experimental & Clinical Cancer Research, 2021
PMID34758854

Acknowledgement

As the project lead, I would like to extend my heartfelt gratitude to all the teams involved in this multidisciplinary effort that made this report a reality.

The exceptional quality of our samples and derived data is a testament to the diligence and persistence of the members from the Tumor Biology and Immunology lab, as well as the genomic and bioinformatics core facilities. Your hard work has truly paid off.

We are immensely grateful for the unwavering support of the clinicians, nurses, and lab techs, especially those from our oncology, neurosurgery, and pathology divisions. Your dedication is deeply appreciated.

A big thank you to our Advanced Application team for their continued improvements to the PRIME application, which has been instrumental in collecting, annotating, and representing the data in this report. Special thanks to the research operation team for facilitating our work and to the clinical research coordinators for meticulously reviewing the clinical records and data.

Lastly, a special note of thanks to Ms. Asma Jamil for her pivotal role in bringing all parts of this report together, to Ms. Noor Faisal and Mr. Muhammad Abdullah Imran Tahir for producing the report, and to Farhana Habib for the final editing. Your contributions have been invaluable.

Dr. Wouter Hendrickx

Principal Investigator of the Pediatric Precision Oncology Initiative
Tumor Biology and Immunology Lab
Sidra Medicine
E: whendrickx@sidra.org

With the kind endorsement of Qatar Cancer Society



Sidra Medicine
Pediatric Oncology Report 2023

www.sidra.org



Doha, Qatar